分析雷贝拉唑三联疗法治疗耐药性HP相关性消化性溃疡的临床疗效  

To Analyze the Clinical Efficacy of Rabeprazole Triple Therapy in the Treatment of Drug-resistant Hp-associated Peptic Ulcer

作　　者：刘飞 LIU Fei(Department of Gastroenterology,Pulandian District Central Hospital,Dalian 116200,China)

机构地区：[1]辽宁省大连市普兰店区中心医院消化内科,辽宁大连116200

出　　处：《中国医药指南》2020年第19期113-114,共2页Guide of China Medicine

摘　　要：目的研究分析耐药性HP相关性消化性溃疡的相关发病机制,探讨对于耐药性HP相关性消化性溃疡的有效治疗方法。分析雷贝拉唑、甲硝唑、阿莫西林三联疗法治疗耐药性HP相关性消化性溃疡的临床疗效、安全性、复发的预防效果,以及该治疗方式的优越性。方法选取2017年1月至2018年12月我院收治的耐药性HP相关性溃疡患者150例。采用随机数字表法将所选患者分成观察组与对照组,两组患者例数均为75例。观察组患者采用雷贝拉唑、甲硝唑、阿莫西林三联方式进行治疗,对照组患者采用奥美拉唑联合阿莫西林进行治疗。对比分析两组患者治疗后疗效情况、不良反应发生情况以及HP根治效果、治疗后复发率以及相关不良反应发生率情况等。结果观察组患者治疗后总有效率显(97.33%)著高于对照组(88.00%),(P <0.05)差异具有统计学意义。观察组患者治疗后14C呼气试验阳性率(14.67%)显著低于对照组(28.00%),(P <0.05)差异具有统计学意义。两组患者(观察组14.67%,对照组12.00%)用药后相关不良反应发生率比较无明显差异,(P> 0.05)差异不具有统计学意义。随访半年,观察组患者复发率(4.00%)显著低于对照组(14.67%),(P <0.05)差异具有统计学意义。结论 HP感染是消化性溃疡发病以及治疗后复发的主要危险因素。雷贝拉唑、甲硝唑与阿莫西林三联方式治疗耐药性HP相关性溃疡的临床疗效确切,能有效根治HP感染,能有效预防消化性溃疡的复发,同时其药物不良反应发生率与奥美拉唑+阿莫西林治疗相比无明显增多,其用药安全性可以得到保障,值得在临床上广泛推广应用。Objective To study and analyze the pathogenesis of drug-resistant hp-associated peptic ulcer and explore effective treatment methods for drug-resistant hp-related peptic ulcer.To analyze the clinical efficacy,safety,recurrence prevention and the superiority of the triple therapy of rabeprazole,metronidazole and amoxicillin in the treatment of hp-resistant peptic ulcer.Methods 150 patients with hp-resistant associated ulcer admitted to our hospital from January 2017 to December 2018 were selected.The patients were divided into observation group and control group by random number table method.The number of patients in both groups was 75.The observation group was treated with rabeprazole,metronidazole and amoxicillin,while the control group was treated with omeprazole combined with amoxicillin.The efficacy,adverse reactions,HP radical cure,recurrence rate and incidence of related adverse reactions of the two groups were compared and analyzed.Results The total effective rate in the observation group(97.33%)was significantly higher than that in the control group(88.00%),and the difference was statistically significant(P<0.05).After treatment,the positive rate of 14C breath test in the observation group(14.67%)was significantly lower than that in the control group(28.00%),and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of related adverse reactions between the two groups(14.67%in the observation group and 12.00%in the control group),and the difference was not statistically significant(P>0.05).Follow-up for half a year showed that the recurrence rate(4.00%)in the observation group was significantly lower than that in the control group(14.67%),and the difference(P<0.05)was statistically significant.Conclusion HP infection is the main risk factor for peptic ulcer and its recurrence after treatment.Rabeprazole etc,the joint treatment of metronidazole and amoxicillin resistance HP related to ulcer clinical curative effect,can effectively cure HP infection,can effe

关 键 词：雷贝拉唑 三联疗法 耐药性 幽门螺杆菌 消化性溃疡 疗效 

分 类 号：R573.1[医药卫生—消化系统]